"The fact that it was a simple blood test, it was absolutely objective, and it was…non-invasive…made it very attractive," says William J. Catalona, MD.
As part of the Urology Times' 50th Anniversary Innovation Celebration, William J. Catalona, MD, discusses how prostate-specific antigen (PSA) testing has greatly impacted the field of urology over the past 50 years. Catalona is a professor of urology at Northwestern University in Chicago, Illinois.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.